Gene-Expression Profile of Steroid-Refractory Acute Graft-Versus-Host Disease.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4549-4549
Author(s):  
Jan Verner ◽  
Jitka Kabathova ◽  
Zbynek Zdrahal ◽  
Alexandra Tomancova ◽  
Jana Volejnikova ◽  
...  

Abstract Abstract 4549 Steroid-refractory acute graft-versus-host disease (aGVHD) remains to be the major complication of allogeneic hematopoietic stem cells transplantation (allo-HSCT). aGVHD is characterized by tissue injury and is associated with high morbidity and mortality, most notably in cases of severe course and/or resistance to corticoids. aGVHD appears usually within the first 100 days after transplantation. This study should lead to identification of molecular patterns characterizing patients’ sensitivity or resistance to corticoid therapy. We performed an oligonucleotide microarray analysis (whole genome Human OneArray, Phalanx) of 13 patients with hematological malignancies who received allo-HSCT. Peripheral blood samples were collected at the time of aGVHD manifestation and subsequently mononuclear cells were isolated (Ficoll-Paque gradient). In total, five patients with resistance, and eight patients with sensitivity to corticoids were included in the analysis. The significance analysis of micorarrays (SAM) revealed a set of differentially expressed genes: GBP5 (guanylate binding protein 5), PRG3 (proteoglycan 3), CDK5RAP2 (CDK5 regulatory subunit associated protein 2), and, especially, ARG1 gene (arginase, liver) whose expression was significantly higher in the group of resistant patients (with 4.89-fold change). As published earlier, arginase is released from human granulocytes during purulent inflammatory reactions and induces a suppression of T-cell proliferation and cytokine synthesis (Munder et al., 2006). These findings might confirm our hypothesis that expression levels of ARG1 gene could reflect the severity of aGVHD. ARG1 gene was detected apparently in a fraction of immature forms of granulocytes which are released into the peripheral blood after allo-HSCT. Thus, both immature granulocytes and mononuclear cells are then isolated using Ficoll-Paque gradient. To validate arginase as a marker of unfavorable grade of aGVHD, it is necessary to examine expression profile of ARG1 gene in neutrophils. Therefore, it is important to separate both mature and immature forms of neutrophils (using different method than Ficoll gradient), as well as examine gene expression profile of a down-regulated CD3ζ chain in T-cells. Down-regulation of CD3ζ chain is due to arginase-mediated depletion of arginine in the T-cell environment (Munder et al., 2006). We assume that ARG1 gene expression profile might have a potential to influence patients′ response to corticoid therapy of unfavorable grade of aGVHD. This study is in progress and further analyses will be focused on monitoring of ARG1 and CD3ζ chain expression levels in a larger cohort. Supported by IGA MZ CR NS9683-4/2008 and MSMT CR MSM0021622430. Disclosures: No relevant conflicts of interest to declare.

2008 ◽  
Vol 17 (5) ◽  
pp. 489-494 ◽  
Author(s):  
Matthew P. Buzzeo ◽  
Jie Yang ◽  
George Casella ◽  
Vijay Reddy

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 7026-7026
Author(s):  
Joseph Rimando ◽  
Steven Larrick ◽  
Nicholas Fowler ◽  
Luciano Castiello ◽  
Syed Abbas Ali ◽  
...  

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2056-2056
Author(s):  
Qifa Liu ◽  
Ke Zhao ◽  
Can Liu ◽  
Meiqing Wu ◽  
Yu Zhang ◽  
...  

Abstract Background Mesenchymal stem cells (MSCs) have been considered as a promising strategy for the prevention and treatment of acute graft-versus-host disease (aGVHD), but the mechanism of MSCs ameliorating GVHD is still not fully understood. A few studies suggested that MSCs ameliorated GVHD via protecting and repairing the function of thymus. Methods Twenty refractory aGVHD patients receiving MSCs treatment were enrolled in this study, and twenty grade II to IV aGVHD patients treated without MSCs were matched as non-MSCs group. MSCs were given at a median dose of 1×106 cells/kg once weekly until aGVHD got complete response (CR) or MSCs were infused for a total of 8 doses. Lymphocyte subsets of T-cell, B-cell, and NK-cell in peripheral blood were analyzed by flow cytometry before and 30, 60, 90, 180 and 360 days after the MSC infusion in MSC group and the corresponding period in the control group. Results A total of the 33 patients who survived more than 30 days after the study treatments were evaluated for the alterations in cellular immune compartment and cGVHD, including 15 cases in MSCs group and 18 in non-MSCs group. In MSCs group, patients had a significantly higher CD4+/CD8+ T-cell ratio at 60, 90 and 180 day after MSCs treatments, which subsequently equalized at 360 day compared with non-MSCs group. The MSC group presented higher percentages of CD4+CD25+ regulatory T cells (Treg) comparing with non-MSCs group, especially at 90 and 180 day, and approached at 360 day. The proportion of CD4+CD45RO+ and CD4+CD45RA+ naïve T-cells in MSC group were also higher than those in non-MSCs group at 60, 90 and 180 day, but not different at 360 day. The proportion of CD19+ and CD16+CD56+ was not detected striking difference between the two groups. Four patients (26.7%) experienced cGVHD in MSCs group, compared with twelve (66.7%) in non-MSCs group (p=0.02). Conclusions In conclusion, our data indicate that MSCs might ameliorate aGVHD and induce longer-lasting immune tolerance by altering cellular immune compartments in peripheral blood. The alteration of the cellular immune compartments is associated with the protecting and repairing role of MSCs to thymus. Disclosures: Liu: 863 Program (No. 2011AA020105): Research Funding; National Public Health Grand Research Foundation (Grant No. 201202017): Research Funding; National Natural Science Foundation of China (Grant No.81000231, No.81270647): Research Funding; Science and Technology Program of Guangzhou of China (11A72121174) : Research Funding.


2019 ◽  
Vol 25 (3) ◽  
pp. S295
Author(s):  
Shernan G. Holtan ◽  
Ashraf Shabaneh ◽  
Armin Rashidi ◽  
Brian Christopher Betts ◽  
Margaret L. MacMillan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document